Allergy & Immunology | Page 8 of 37 | Links Medicus Content Curation & Alerts in Medicine

SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact https://t.co/dd91AkYmu4 pic.twitter.com/1ByzLeTdlh

— Nature Rev Immunol (@NatRevImmunol) December 7, 2021

[Press release – not published yet] Lab study suggests a third dose (booster) of the Pfizer–BioNTech vaccine may be necessary to provide an adequate immune response to the Omicron variant.

9 Dec, 2021 | 10:29h | UTC

Press release: Pfizer and Biontech provide update on Omicron variant

Commentaries:

Omicron likely to weaken COVID vaccine protection – Nature

Pfizer-BioNTech says COVID booster should protect against Omicron – CIDRAP

Expert reaction to press release from Pfizer-BioNTech about omicron and neutralising antibody titres after two and three vaccine doses – Science Media Centre

Covid: Pfizer says booster shot promising against Omicron – BBC

Pfizer-BioNTech Covid-19 shot loses power against Omicron variant, but booster restores protection – STAT

Multiple early studies find notable Omicron vaccine evasion.

9 Dec, 2021 | 10:26h | UTC

Multiple early studies find notable Omicron vaccine evasion – CIDRAP

RCT: Among children between the ages of 6 and 11 years with uncontrolled moderate-to-severe asthma, add-on Dupilumab reduced exacerbations and improved lung function.

9 Dec, 2021 | 10:21h | UTC

Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma – New England Journal of Medicine

Commentary: International study supports dupilumab for treatment of moderate-to-severe asthma in children – Vanderbilt University Medical Center

A first, small study suggests Omicron is a larger threat to Covid-19 immunity than other variants.

8 Dec, 2021 | 10:22h | UTC

A first, small study suggests Omicron is a larger threat to Covid-19 immunity than other variants – STAT

Original Study: SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection – medRxiv

Commentary from the author on Twitter (thread – click for more)

We have completed our first experiments on neutralization of Omicron by Pfizer BNT162b2 vaccination elicited immunity

Manuscript available at https://t.co/rGaEB9GdmS

and should be available on medRxiv in the coming days

— Alex Sigal (@sigallab) December 7, 2021

Beyond Omicron: what’s next for COVID’s viral evolution.

8 Dec, 2021 | 10:06h | UTC

Beyond Omicron: what’s next for COVID’s viral evolution – Nature

Study shows increased immunogenicity of extended mRNA SARS-CoV-2 vaccine dosing intervals.

7 Dec, 2021 | 10:21h | UTC

Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals – JAMA

Commentary on Twitter (thread – click for more)

1/ Not surprisingly, a longer delay between 1st & 2nd doses of mRNA COVID vaccines (i.e. 6-7 weeks rather than 3-4 weeks) results in better immune responses.https://t.co/XhiU6u0hYb

— Céline Gounder, MD, ScM, FIDSA 🇺🇦 (@celinegounder) December 3, 2021

Six different COVID-19 boosters are safe and increase immunity when given after two doses of AstraZeneca or Pfizer-BioNTech, with significant variations in immune responses, UK trial shows.

5 Dec, 2021 | 23:57h | UTC

News Release: Six different COVID-19 boosters are safe and increase immunity when given after two doses of AstraZeneca or Pfizer-BioNTech, with large variations in immune responses, UK trial shows – The Lancet

Original Study: Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial – The Lancet

Commentaries:

Six different COVID-19 boosters induce variable immune response – CIDRAP

Covid booster shots significantly strengthen immunity, trial finds – The Guardian

Expert reaction to COV-BOOST study investigating safety and immunogenicity of seven COVID-19 vaccines as a third dose following two doses of either Oxford-AstraZeneca or Pfizer – Science Media Centre

Commentary on Twitter

NEW—Six different COVID-19 boosters are safe and increase immunity when given after two doses of #AstraZeneca or #Pfizer-BioNTech, with large variations in immune responses, UK trial shows. https://t.co/ktUp1m2Rsb pic.twitter.com/wlwxcLYDm1

— The Lancet (@TheLancet) December 2, 2021

Omicron is supercharging the COVID vaccine booster debate – “The data are growing that booster jabs enhance protection — but their durability, impact and ability to quash the new variant are unknown”.

3 Dec, 2021 | 10:19h | UTC

Omicron is supercharging the COVID vaccine booster debate – Nature

Systematic Review: Phototherapy for atopic eczema.

3 Dec, 2021 | 10:03h | UTC

Phototherapy for atopic eczema – Cochrane Library

Summary: What are the benefits and risks of visible light therapy for treating atopic eczema (also known as eczema or atopic dermatitis)? – Cochrane Library

Commentary on Twitter

https://twitter.com/CochraneUK/status/1457046637134630920

Cohort study: Allergic conditions linked to lower COVID-19 infection risk.

1 Dec, 2021 | 08:52h | UTC

News Release: Allergic conditions linked to lower COVID-19 infection risk – BMJ

Original Study: Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK) – Thorax

Heavily mutated coronavirus variant puts scientists on alert – “Researchers are racing to determine whether a fast-spreading variant in South Africa poses a threat to COVID vaccines’ effectiveness”.

26 Nov, 2021 | 08:42h | UTC

Heavily mutated coronavirus variant puts scientists on alert – Nature

[Preprint] Serological responses to COVID-19 booster vaccine in England.

26 Nov, 2021 | 08:34h | UTC

Serological responses to COVID-19 booster vaccine in England – medRxiv

Commentary from the author on Twitter (thread – click for more)

1/ Our preprint on #SARSCoV2 antibody responses in UK adults receiving a #COVID19 vaccine booster with the Pfizer vaccine at least 6 months after primary immunisation with Pfizer or AZ vaccine, which was given at an extended interval (8-12 wks) … 🧵

👉 https://t.co/JYxwH4JM51

— Shamez Ladhani (@ShamezLadhani) November 25, 2021

A population-based cohort study in Qatar showed reinfections had 90% lower odds of resulting in hospitalization or death than primary infections.

25 Nov, 2021 | 10:46h | UTC

Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections – New England Journal of Medicine

AAP Clinical Report: Biologics for Asthma and Allergic Skin Diseases in Children.

19 Nov, 2021 | 10:34h | UTC

Biologics for Asthma and Allergic Skin Diseases in Children – Pediatrics

Phase 4 RCT: Concomitant administration of COVID-19 vaccines (AstraZeneca or Pfizer) with seasonal influenza vaccines in adults is safe and preserves antibody responses to both vaccines.

14 Nov, 2021 | 20:14h | UTC

Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial – The Lancet

Opinion | Protective immunity after recovery from SARS-CoV-2 infection.

10 Nov, 2021 | 07:15h | UTC

Protective immunity after recovery from SARS-CoV-2 infection – The Lancet Infectious Diseases

Commentary on Twitter

"Policy makers should consider recovery from previous SARS-CoV-2 infection equal to immunity from vaccination for purposes related to entry to public events, businesses, and the workplace,or travel requirements"
Do you agree with this?
I don't #IDtwitter https://t.co/FHbgXILD8Z

— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) November 9, 2021